BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29:321-347. [PMID: 26960938 DOI: 10.1128/cmr.00068-15] [Cited by in Crossref: 232] [Cited by in F6Publishing: 99] [Article Influence: 38.7] [Reference Citation Analysis]
Number Citing Articles
1 Scortti M, Han L, Alvarez S, Leclercq A, Moura A, Lecuit M, Vazquez-Boland J. Epistatic control of intrinsic resistance by virulence genes in Listeria. PLoS Genet 2018;14:e1007525. [PMID: 30180166 DOI: 10.1371/journal.pgen.1007525] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
2 Krucinska J, Lombardo MN, Erlandsen H, Hazeen A, Duay SS, Pattis JG, Robinson VL, May ER, Wright DL. Functional and structural basis of E. coli enolase inhibition by SF2312: a mimic of the carbanion intermediate. Sci Rep 2019;9:17106. [PMID: 31745118 DOI: 10.1038/s41598-019-53301-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kanchanasurakit S, Santimaleeworagun W, McPherson CE, Piriyachananusorn N, Boonsong B, Katwilat P, Saokaew S. Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection. Infect Chemother 2020;52:516-29. [PMID: 33124216 DOI: 10.3947/ic.2020.52.4.516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Milner KA, Bay DC, Alexander D, Walkty A, Karlowsky JA, Mulvey MR, Sharma MK, Zhanel GG. Identification and Characterization of a Novel FosA7 Member from Fosfomycin-Resistant Escherichia coli Clinical Isolates from Canadian Hospitals. Antimicrob Agents Chemother 2020;65:e00865-20. [PMID: 33077665 DOI: 10.1128/AAC.00865-20] [Reference Citation Analysis]
5 Mączyńska B, Paleczny J, Oleksy-Wawrzyniak M, Choroszy-Król I, Bartoszewicz M. In Vitro Susceptibility of Multi-Drug Resistant Klebsiellapneumoniae Strains Causing Nosocomial Infections to Fosfomycin. A Comparison of Determination Methods. Pathogens 2021;10:512. [PMID: 33922754 DOI: 10.3390/pathogens10050512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gazal LES, Medeiros LP, Dibo M, Nishio EK, Koga VL, Gonçalves BC, Grassotti TT, de Camargo TCL, Pinheiro JJ, Vespero EC, de Brito KCT, de Brito BG, Nakazato G, Kobayashi RKT. Detection of ESBL/AmpC-Producing and Fosfomycin-Resistant Escherichia coli From Different Sources in Poultry Production in Southern Brazil. Front Microbiol 2020;11:604544. [PMID: 33505374 DOI: 10.3389/fmicb.2020.604544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mothibi LM, Bosman NN, Nana T. Fosfomycin susceptibility of uropathogens at Charlotte Maxeke Johannesburg Academic Hospital. S Afr J Infect Dis 2020;35:173. [PMID: 34485478 DOI: 10.4102/sajid.v35i1.173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Raina D, Kumar C, Kumar V, Khan IA, Saran S. Potential Inhibitors Targeting Escherichia coli UDP-N-Acetylglucosamine Enolpyruvyl Transferase (MurA): An Overview. Indian J Microbiol 2022;62:11-22. [DOI: 10.1007/s12088-021-00988-6] [Reference Citation Analysis]
9 Sorlozano-Puerto A, Lopez-Machado I, Albertuz-Crespo M, Martinez-Gonzalez LJ, Gutierrez-Fernandez J. Characterization of Fosfomycin and Nitrofurantoin Resistance Mechanisms in Escherichia coli Isolated in Clinical Urine Samples. Antibiotics (Basel) 2020;9:E534. [PMID: 32847131 DOI: 10.3390/antibiotics9090534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Antonello RM, Principe L, Maraolo AE, Viaggi V, Pol R, Fabbiani M, Montagnani F, Lovecchio A, Luzzati R, Di Bella S. Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies. Antibiotics (Basel) 2020;9:E500. [PMID: 32785114 DOI: 10.3390/antibiotics9080500] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
11 Satlin MJ, Walsh TJ. Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2017;19:e12762. [PMID: 28815897 DOI: 10.1111/tid.12762] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 8.6] [Reference Citation Analysis]
12 Singhal T, Rodrigues C, Soman R, Wattal C, Swaminathan S, Nambi S, Talwar D, Singh RK, Todi S. Treatment of MRSA infections in India: Clinical insights from a Delphi analysis. Indian J Med Microbiol 2021:S0255-0857(21)04713-7. [PMID: 34785281 DOI: 10.1016/j.ijmmb.2021.11.005] [Reference Citation Analysis]
13 Wang L, Di Luca M, Tkhilaishvili T, Trampuz A, Gonzalez Moreno M. Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms. Front Microbiol 2019;10:2522. [PMID: 31781056 DOI: 10.3389/fmicb.2019.02522] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
14 Yu H, Yang H, Shi E, Tang W. Development and Clinical Application of Phosphorus-Containing Drugs. Med Drug Discov 2020;8:100063. [PMID: 32864606 DOI: 10.1016/j.medidd.2020.100063] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Nwabor OF, Terbtothakun P, Voravuthikunchai SP, Chusri S. Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem-Resistant Acinetobacter baumannii. Pharmaceuticals (Basel) 2021;14:185. [PMID: 33668905 DOI: 10.3390/ph14030185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Bakthavatchalam YD, Shankar A, Muthuirulandi Sethuvel DP, Asokan K, Kanthan K, Veeraraghavan B. Synergistic activity of fosfomycin-meropenem and fosfomycin-colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence. Future Sci OA 2020;6:FSO461. [PMID: 32257374 DOI: 10.2144/fsoa-2019-0074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA; Antibacterial Resistance Leadership Group. Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. Antimicrob Agents Chemother 2018;62:e00464-18. [PMID: 29891606 DOI: 10.1128/AAC.00464-18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
18 Hager FF, Sützl L, Stefanović C, Blaukopf M, Schäffer C. Pyruvate Substitutions on Glycoconjugates. Int J Mol Sci 2019;20:E4929. [PMID: 31590345 DOI: 10.3390/ijms20194929] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Putensen C, Ellger B, Sakka SG, Weyland A, Schmidt K, Zoller M, Weiler N, Kindgen-Milles D, Jaschinski U, Weile J, Lindau S, Kieninger M, Faltlhauser A, Jung N, Teschendorf P, Adamzik M, Gründling M, Wahlers T, Gerlach H, Litty FA. Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection 2019;47:827-36. [PMID: 31190298 DOI: 10.1007/s15010-019-01323-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
20 Cattoir V, Pourbaix A, Magnan M, Chau F, de Lastours V, Felden B, Fantin B, Guérin F. Novel Chromosomal Mutations Responsible for Fosfomycin Resistance in Escherichia coli. Front Microbiol 2020;11:575031. [PMID: 33193186 DOI: 10.3389/fmicb.2020.575031] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Brennan-Krohn T, Manetsch R, O'Doherty GA, Kirby JE. New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae. Transl Res 2020;220:14-32. [PMID: 32201344 DOI: 10.1016/j.trsl.2020.02.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
22 Lee IPA, Andam CP. Pan-genome diversification and recombination in Cronobacter sakazakii, an opportunistic pathogen in neonates, and insights to its xerotolerant lifestyle. BMC Microbiol 2019;19:306. [PMID: 31881843 DOI: 10.1186/s12866-019-1664-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Liu Y, Li H, Zhang Y, Ye Y, Gao Y, Li J. In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates. Infect Drug Resist 2019;12:1619-28. [PMID: 31354311 DOI: 10.2147/IDR.S208071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Perveen S, Sharma R. Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery. Biochem Pharmacol 2022;197:114906. [PMID: 34990594 DOI: 10.1016/j.bcp.2021.114906] [Reference Citation Analysis]
25 Ortega-Trejo JA, Pérez-Villalva R, Arreola-Guerra JM, Ramírez V, Sifuentes-Osornio J, Bobadilla NA. Effect of Fosfomycin on Cyclosporine Nephrotoxicity. Antibiotics (Basel) 2020;9:E720. [PMID: 33096599 DOI: 10.3390/antibiotics9100720] [Reference Citation Analysis]
26 Álvarez-Martínez FJ, Barrajón-Catalán E, Micol V. Tackling Antibiotic Resistance with Compounds of Natural Origin: A Comprehensive Review. Biomedicines 2020;8:E405. [PMID: 33050619 DOI: 10.3390/biomedicines8100405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
27 Tamma PD, Bonomo RA, Stiefel U. The Role of Intravenous Fosfomycin: Finding Our Way Out of Dante's Forest Dark. JAMA Netw Open 2022;5:e2138691. [PMID: 35024841 DOI: 10.1001/jamanetworkopen.2021.38691] [Reference Citation Analysis]
28 Rehman MA, Yin X, Persaud-Lachhman MG, Diarra MS. First Detection of a Fosfomycin Resistance Gene, fosA7, in Salmonella enterica Serovar Heidelberg Isolated from Broiler Chickens. Antimicrob Agents Chemother 2017;61:e00410-17. [PMID: 28533247 DOI: 10.1128/AAC.00410-17] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 8.2] [Reference Citation Analysis]
29 Boucard J, Boudjemaa R, Steenkeste K, Jacqueline C, Stephant N, Lefèvre F, Laurent AD, Lartigue L, Hulin P, Nedellec S, Fontaine-aupart M, Ishow E. Phosphonic Acid Fluorescent Organic Nanoparticles for High-Contrast and Selective Staining of Gram-Positive Bacteria. ACS Omega 2018;3:17392-402. [DOI: 10.1021/acsomega.8b02603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
30 Zhang F, Zhai T, Haider S, Liu Y, Huang ZJ. Synergistic Effect of Chlorogenic Acid and Caffeic Acid with Fosfomycin on Growth Inhibition of a Resistant Listeria monocytogenes Strain. ACS Omega 2020;5:7537-44. [PMID: 32280897 DOI: 10.1021/acsomega.0c00352] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
31 Fedrigo NH, Mazucheli J, Albiero J, Shinohara DR, Lodi FG, Machado ACDS, Sy SKB, Tognim MCB. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities. Antimicrob Agents Chemother 2017;61:e02498-16. [PMID: 28607025 DOI: 10.1128/AAC.02498-16] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
32 Thaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 2017;8:403-16. [PMID: 27384881 DOI: 10.1080/21505594.2016.1207834] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 9.8] [Reference Citation Analysis]
33 Nordmann P, Poirel L, Mueller L. Rapid Detection of Fosfomycin Resistance in Escherichia coli. J Clin Microbiol 2019;57:e01531-18. [PMID: 30381418 DOI: 10.1128/JCM.01531-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
34 Wang J, Wang Y, Wang ZY, Wu H, Mei CY, Shen PC, Pan ZM, Jiao X. Chromosomally Located fosA7 in Salmonella Isolates From China. Front Microbiol 2021;12:781306. [PMID: 35027914 DOI: 10.3389/fmicb.2021.781306] [Reference Citation Analysis]
35 Antonello RM, Di Bella S, Maraolo AE, Luzzati R. Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies. Eur J Clin Microbiol Infect Dis 2021;40:1117-26. [PMID: 33604721 DOI: 10.1007/s10096-021-04181-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Bassetti M, Garau J. Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. J Antimicrob Chemother 2021;76:iv23-37. [PMID: 34849997 DOI: 10.1093/jac/dkab352] [Reference Citation Analysis]
37 Zhanel GG, Zhanel MA, Karlowsky JA. Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada. Can J Infect Dis Med Microbiol 2018;2018:8912039. [PMID: 30046362 DOI: 10.1155/2018/8912039] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
38 Silver LL. Fosfomycin: Mechanism and Resistance. Cold Spring Harb Perspect Med 2017;7:a025262. [PMID: 28062557 DOI: 10.1101/cshperspect.a025262] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 18.4] [Reference Citation Analysis]
39 Liu BH, Lei CW, Zhang AY, Pan Y, Kong LH, Xiang R, Wang YX, Yang YX, Wang HN. Colocation of the Multiresistance Gene cfr and the Fosfomycin Resistance Gene fosD on a Novel Plasmid in Staphylococcus arlettae from a Chicken Farm. Antimicrob Agents Chemother 2017;61:e01388-17. [PMID: 28923876 DOI: 10.1128/AAC.01388-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
40 Surleac M, Czobor Barbu I, Paraschiv S, Popa LI, Gheorghe I, Marutescu L, Popa M, Sarbu I, Talapan D, Nita M, Iancu AV, Arbune M, Manole A, Nicolescu S, Sandulescu O, Streinu-Cercel A, Otelea D, Chifiriuc MC. Whole genome sequencing snapshot of multi-drug resistant Klebsiella pneumoniae strains from hospitals and receiving wastewater treatment plants in Southern Romania. PLoS One 2020;15:e0228079. [PMID: 31999747 DOI: 10.1371/journal.pone.0228079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
41 Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis 2020;7:2049936120912049. [PMID: 32489663 DOI: 10.1177/2049936120912049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
42 Giurazza R, Mazza MC, Andini R, Sansone P, Pace MC, Durante-Mangoni E. Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections. Life (Basel) 2021;11:519. [PMID: 34204961 DOI: 10.3390/life11060519] [Reference Citation Analysis]
43 Ito R, Tomich AD, McElheny CL, Mettus RT, Sluis-Cremer N, Doi Y. Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens. Antimicrob Agents Chemother 2017;61:e01424-17. [PMID: 28993329 DOI: 10.1128/AAC.01424-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
44 Xie N, Jiang L, Chen M, Zhang G, Liu Y, Li J, Huang X. In vitro and in vivo Antibacterial Activity of Linezolid Plus Fosfomycin Against Staphylococcus aureus with Resistance to One Drug. Infect Drug Resist 2021;14:639-49. [PMID: 33658805 DOI: 10.2147/IDR.S290332] [Reference Citation Analysis]
45 Sevrain CM, Berchel M, Couthon H, Jaffrès PA. Phosphonic acid: preparation and applications. Beilstein J Org Chem 2017;13:2186-213. [PMID: 29114326 DOI: 10.3762/bjoc.13.219] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 10.8] [Reference Citation Analysis]
46 Zirpe KG, Mehta Y, Pandit R, Pande R, Deshmukh AM, Patil S, Bhagat S, Barkate H. A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients. Indian J Crit Care Med 2021;25:1055-8. [PMID: 34963727 DOI: 10.5005/jp-journals-10071-23958] [Reference Citation Analysis]
47 Pujol M, Miró JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, Pigrau C, Calbo E, Montejo M, Rodriguez-Álvarez R, Garcia-Pais MJ, Pintado V, Escudero-Sánchez R, Lopez-Contreras J, Morata L, Montero M, Andrés M, Pasquau J, Arenas MD, Padilla B, Murillas J, Jover-Sáenz A, López-Cortes LE, García-Pardo G, Gasch O, Videla S, Hereu P, Tebé C, Pallarès N, Sanllorente M, Domínguez MÁ, Càmara J, Ferrer A, Padullés A, Cuervo G, Carratalà J; MRSA Bacteremia (BACSARM) Trial Investigators. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. Clin Infect Dis 2021;72:1517-25. [PMID: 32725216 DOI: 10.1093/cid/ciaa1081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
48 Hashemian SMR, Farhadi Z, Farhadi T. Fosfomycin: the characteristics, activity, and use in critical care. Ther Clin Risk Manag 2019;15:525-30. [PMID: 30988619 DOI: 10.2147/TCRM.S199119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
49 Garg A, Garg J, Kumar S, Bhattacharya A, Agarwal S, Upadhyay GC. Molecular epidemiology & therapeutic options of carbapenem-resistant Gram-negative bacteria. Indian J Med Res 2019;149:285-9. [PMID: 31219096 DOI: 10.4103/ijmr.IJMR_36_18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
50 Simon MA, Ongpipattanakul C, Nair SK, van der Donk WA. Biosynthesis of fosfomycin in pseudomonads reveals an unexpected enzymatic activity in the metallohydrolase superfamily. Proc Natl Acad Sci U S A 2021;118:e2019863118. [PMID: 34074759 DOI: 10.1073/pnas.2019863118] [Reference Citation Analysis]
51 Trecarichi EM, Tumbarello M. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence 2017;8:470-84. [PMID: 28276996 DOI: 10.1080/21505594.2017.1292196] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 14.2] [Reference Citation Analysis]
52 Kyriakopoulos AM, Nagl M, Orth-Höller D, Marcinkiewicz J, Baliou S, Zoumbourlis V. Successful treatment of a unique chronic multi-bacterial scalp infection with N-chlorotaurine, N-bromotaurine and bromamine T. Access Microbiol 2020;2:acmi000126. [PMID: 32974590 DOI: 10.1099/acmi.0.000126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Wald-Dickler N, Lee TC, Tangpraphaphorn S, Butler-Wu SM, Wang N, Degener T, Kan C, Phillips MC, Cho E, Canamar C, Holtom P, Spellberg B. Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study. Open Forum Infect Dis 2022;9:ofab620. [PMID: 35036466 DOI: 10.1093/ofid/ofab620] [Reference Citation Analysis]
54 Bielen L, Likic R. Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Ther Adv Infect Dis 2019;6:2049936119858883. [PMID: 31258896 DOI: 10.1177/2049936119858883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
55 Fonnes S, Holzknecht BJ, Arpi M, Rosenberg J. Intraperitoneal administration of fosfomycin, metronidazole, and granulocyte-macrophage colony-stimulating factor in patients undergoing appendectomy is safe: a phase II clinical trial. Sci Rep 2019;9:6727. [PMID: 31040341 DOI: 10.1038/s41598-019-43151-4] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Fiore M, Di Franco S, Alfieri A, Passavanti MB, Pace MC, Petrou S, Martora F, Leone S. Spontaneous bacterial peritonitis due to carbapenemase-producing Enterobacteriaceae: Etiology and antibiotic treatment. World J Hepatol 2020; 12(12): 1136-1147 [PMID: 33442443 DOI: 10.4254/wjh.v12.i12.1136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Mannucci C, Dante G, Miroddi M, Facchinetti F, D'Anna R, Santamaria A, Lenti MC, Vannacci A, Calapai F, Perone M, Migliardi G, Alibrandi A, Navarra M, Calapai G. Vigilance on use of drugs, herbal products, and food supplements during pregnancy: focus on fosfomycin. J Matern Fetal Neonatal Med 2019;32:125-8. [PMID: 28868940 DOI: 10.1080/14767058.2017.1373761] [Reference Citation Analysis]
58 Al-Aloul M, Nazareth D, Walshaw M. The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis. Clin Kidney J 2019;12:652-8. [PMID: 31583092 DOI: 10.1093/ckj/sfz005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
59 Ito R, Mustapha MM, Tomich AD, Callaghan JD, McElheny CL, Mettus RT, Shanks RMQ, Sluis-Cremer N, Doi Y. Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene. mBio 2017;8:e00749-17. [PMID: 28851843 DOI: 10.1128/mBio.00749-17] [Cited by in Crossref: 74] [Cited by in F6Publishing: 50] [Article Influence: 14.8] [Reference Citation Analysis]
60 Abbott IJ, van Gorp E, Wijma RA, Meletiadis J, Roberts JA, Mouton JW, Peleg AY. Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome. Antimicrob Agents Chemother 2020;64:e01982-19. [PMID: 31907184 DOI: 10.1128/AAC.01982-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
61 Soman R, Bakthavatchalam YD, Nadarajan A, Dwarakanathan HT, Venkatasubramanian R, Veeraraghavan B. Is it time to move away from polymyxins?: evidence and alternatives. Eur J Clin Microbiol Infect Dis 2021;40:461-75. [PMID: 33009595 DOI: 10.1007/s10096-020-04053-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
62 Singkham-In U, Muhummudaree N, Chatsuwan T. fosA3 overexpression with transporter mutations mediates high-level of fosfomycin resistance and silence of fosA3 in fosfomycin-susceptible Klebsiella pneumoniae producing carbapenemase clinical isolates. PLoS One 2020;15:e0237474. [PMID: 32857767 DOI: 10.1371/journal.pone.0237474] [Reference Citation Analysis]
63 Qi C, Xu S, Wu M, Zhu S, Liu Y, Huang H, Zhang G, Li J, Huang X. Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A Galleria mellonella Larval Infection Model. Infect Drug Resist 2019;12:3497-505. [PMID: 31814738 DOI: 10.2147/IDR.S219117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Poirel L, Vuillemin X, Kieffer N, Mueller L, Descombes MC, Nordmann P. Identification of FosA8, a Plasmid-Encoded Fosfomycin Resistance Determinant from Escherichia coli, and Its Origin in Leclercia adecarboxylata. Antimicrob Agents Chemother 2019;63:e01403-19. [PMID: 31481445 DOI: 10.1128/AAC.01403-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
65 Ortiz de la Rosa JM, Nordmann P, Poirel L. Antioxidant Molecules as a Source of Mitigation of Antibiotic Resistance Gene Dissemination. Antimicrob Agents Chemother 2021;65:e02658-20. [PMID: 33753335 DOI: 10.1128/AAC.02658-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Wang G, Yu W, Cui Y, Shi Q, Huang C, Xiao Y. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation. BMC Infect Dis 2021;21:307. [PMID: 33771113 DOI: 10.1186/s12879-021-06000-2] [Reference Citation Analysis]
67 Goto S, Ohbayashi T, Takeshita K, Sone T, Matsuura Y, Mergaert P, Kikuchi Y. A Peptidoglycan Amidase Mutant of Burkholderia insecticola Adapts an L-form-like Shape in the Gut Symbiotic Organ of the Bean Bug Riptortus pedestris. Microbes Environ 2020;35. [PMID: 33177277 DOI: 10.1264/jsme2.ME20107] [Reference Citation Analysis]
68 Rinaldi M, Cojutti PG, Zamparini E, Tedeschi S, Rossi N, Conti M, Giannella M, Pea F, Viale P. Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction. Antimicrob Agents Chemother 2021:AAC. [PMID: 33619055 DOI: 10.1128/AAC.02038-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Blaszczyk AJ, Booker SJ. A (Re)Discovery of the Fom3 Substrate. Biochemistry 2018;57:891-2. [PMID: 29345912 DOI: 10.1021/acs.biochem.7b01281] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Martín-Gutiérrez G, Docobo-Pérez F, Rodriguez-Beltrán J, Rodríguez-Martínez JM, Aznar J, Pascual A, Blázquez J. Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake. Antimicrob Agents Chemother 2018;62:e01899-17. [PMID: 29038268 DOI: 10.1128/AAC.01899-17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
71 Kudzin MH, Mrozińska Z. Biofunctionalization of Textile Materials. 2. Antimicrobial Modification of Poly(lactide) (PLA) Nonwoven Fabricsby Fosfomycin. Polymers (Basel) 2020;12:E768. [PMID: 32244602 DOI: 10.3390/polym12040768] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
72 Chockalingam A, Stewart S, Xu L, Gandhi A, Matta MK, Patel V, Sacks L, Rouse R. Evaluation of Immunocompetent Urinary Tract Infected Balb/C Mouse Model For the Study of Antibiotic Resistance Development Using Escherichia Coli CFT073 Infection. Antibiotics (Basel) 2019;8:E170. [PMID: 31569374 DOI: 10.3390/antibiotics8040170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
73 Wang B, Blaszczyk AJ, Knox HL, Zhou S, Blaesi EJ, Krebs C, Wang RX, Booker SJ. Stereochemical and Mechanistic Investigation of the Reaction Catalyzed by Fom3 from Streptomyces fradiae, a Cobalamin-Dependent Radical S-Adenosylmethionine Methylase. Biochemistry 2018;57:4972-84. [PMID: 30036047 DOI: 10.1021/acs.biochem.8b00693] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
74 Pana ZD, Zaoutis T. Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? F1000Res 2018;7:F1000 Faculty Rev-1347. [PMID: 30228863 DOI: 10.12688/f1000research.14822.1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
75 Harsági N, Keglevich G. The Hydrolysis of Phosphinates and Phosphonates: A Review. Molecules 2021;26:2840. [PMID: 34064764 DOI: 10.3390/molecules26102840] [Reference Citation Analysis]
76 Dos Santos C, Dos Santos LS, Franco OL. Fosfomycin and nitrofurantoin: classic antibiotics and perspectives. J Antibiot (Tokyo) 2021;74:547-58. [PMID: 34244614 DOI: 10.1038/s41429-021-00444-z] [Reference Citation Analysis]
77 Ruiz-Ruigómez M, Fernández-Ruiz M, Silva JT, Vidal E, Origüen J, Calvo-Cano A, Luna-Huerta E, Merino E, Hernández D, Jironda-Gallegos C, Escudero-Sánchez R, Gioia F, Moreno A, Roca C, Cordero E, Janeiro D, Sánchez-Sobrino B, Montero MM, Redondo D, Candel FJ, Pérez-Flores I, Armiñanzas C, González-Rico C, Fariñas MC, Rodrigo E, Loeches B, López-Oliva MO, Montejo M, Lauzurica R, Horcajada JP, Pascual J, Andrés A, Aguado JM, López-Medrano F; REIPI, REDinREN, and GESITRA‐IC/SEIMC. Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients: Results from a Spanish multicenter cohort. Antimicrob Agents Chemother 2021:AAC. [PMID: 33558295 DOI: 10.1128/AAC.02267-20] [Reference Citation Analysis]
78 Petrosillo N, Taglietti F, Granata G. Treatment Options for Colistin Resistant Klebsiella pneumoniae: Present and Future. J Clin Med 2019;8:E934. [PMID: 31261755 DOI: 10.3390/jcm8070934] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
79 Leelawattanachai P, Wattanavijitkul T, Paiboonvong T, Plongla R, Chatsuwan T, Usayaporn S, Nosoongnoen W, Montakantikul P. Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using Monte Carlo Simulation. Antibiotics (Basel) 2020;9:E615. [PMID: 32961833 DOI: 10.3390/antibiotics9090615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Fang Q, Maglangit F, Wu L, Ebel R, Kyeremeh K, Andersen JH, Annang F, Pérez-Moreno G, Reyes F, Deng H. Signalling and Bioactive Metabolites from Streptomyces sp. RK44. Molecules 2020;25:E460. [PMID: 31979050 DOI: 10.3390/molecules25030460] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
81 Suarez JF, Ong'uti S, Holubar M. Select controversies in the management of methicillin-resistant Staphylococcus aureus bacteremia: answers and remaining questions from recent evidence. Fac Rev 2021;10:66. [PMID: 34557870 DOI: 10.12703/r/10-66] [Reference Citation Analysis]
82 Zykov IN, Samuelsen Ø, Jakobsen L, Småbrekke L, Andersson DI, Sundsfjord A, Frimodt-Møller N. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model. Antimicrob Agents Chemother 2018;62:e02560-17. [PMID: 29581117 DOI: 10.1128/AAC.02560-17] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
83 Banerjee S, Sengupta M, Sarker TK. Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens. Indian J Urol 2017;33:149-54. [PMID: 28469304 DOI: 10.4103/iju.IJU_285_16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
84 Li G, Standing JF, Bielicki J, Hope W, van den Anker J, Heath PT, Sharland M. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Drugs 2017;77:941-50. [PMID: 28456943 DOI: 10.1007/s40265-017-0745-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
85 Bielen L, Likić R, Erdeljić V, Mareković I, Firis N, Grgić-Medić M, Godan A, Tomić I, Hunjak B, Markotić A, Bejuk D, Tičić V, Balzar S, Bedenić B. Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study. Croat Med J 2018;59:56-64. [PMID: 29740989 DOI: 10.3325/cmj.2018.59.56] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Cheng K, Fang LX, Ge QW, Wang D, He B, Lu JQ, Zhong ZX, Wang XR, Yu Y, Lian XL, Liao XP, Sun J, Liu YH. Emergence of fosA3 and bla CTX-M- 14 in Multidrug-Resistant Citrobacter freundii Isolates From Flowers and the Retail Environment in China. Front Microbiol 2021;12:586504. [PMID: 33613474 DOI: 10.3389/fmicb.2021.586504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Elliott ZS, Barry KE, Cox HL, Stoesser N, Carroll J, Vegesana K, Kotay S, Sheppard AE, Wailan A, Crook DW, Parikh H, Mathers AJ. The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates. J Clin Microbiol 2019;57:e00634-19. [PMID: 31340992 DOI: 10.1128/JCM.00634-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
88 Narayanasamy S, Nation RL, Mahony AA, Grayson ML, Kwong JC, Sherry NL, Khumra S, Ellis AG, Frauman AG, Holmes NE. Cure of Limb-Threatening XDR Pseudomonas aeruginosa Infection: Combining Genome Sequencing, Therapeutic Drug Level Monitoring, and Surgical Debridement. Open Forum Infect Dis 2021;8:ofaa572. [PMID: 33511225 DOI: 10.1093/ofid/ofaa572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Ruan Z, Cui J, He Z, Guo Y, Jia X, Huang X. Synergistic Effects from Combination of Cryptotanshinone and Fosfomycin Against Fosfomycin-Susceptible and Fosfomycin-Resistant Staphylococcus aureus. Infect Drug Resist 2020;13:2837-44. [PMID: 32884307 DOI: 10.2147/IDR.S255296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Wang J, He JT, Bai Y, Wang R, Cai Y. Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing Klebsiella pneumoniae in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Biomed Res Int 2018;2018:5720417. [PMID: 29850537 DOI: 10.1155/2018/5720417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
91 Huang Y, Lin Q, Zhou Q, Lv L, Wan M, Gao X, Wang C, Liu JH. Identification of fosA10, a Novel Plasmid-Mediated Fosfomycin Resistance Gene of Klebsiella pneumoniae Origin, in Escherichia coli. Infect Drug Resist 2020;13:1273-9. [PMID: 32431524 DOI: 10.2147/IDR.S251360] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
92 Lasko MJ, Nicolau DP. Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. Curr Infect Dis Rep 2020;22:6. [PMID: 32034524 DOI: 10.1007/s11908-020-0716-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
93 Harada K, Shimizu T, Kawaguchi K, Furuhashi T, Ishihara G. Urinary Pharmacokinetic and Pharmacodynamic Profiles of Fosfomycin against Extended-Spectrum β-Lactamase-Producing Escherichia coli with Canine Ex Vivo Modeling: A Pilot Study. Antibiotics (Basel) 2020;9:E230. [PMID: 32380640 DOI: 10.3390/antibiotics9050230] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Vrancianu CO, Dobre EG, Gheorghe I, Barbu I, Cristian RE, Chifiriuc MC. Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections. Microorganisms 2021;9:730. [PMID: 33807464 DOI: 10.3390/microorganisms9040730] [Reference Citation Analysis]
95 Martín-Gutiérrez G, Docobo-Pérez F, Rodríguez-Martínez JM, Pascual A, Blázquez J, Rodriguez-Beltrán J. Detection of Low-Level Fosfomycin-Resistant Variants by Decreasing Glucose-6-Phosphate Concentration in Fosfomycin Susceptibility Determination. Antibiotics (Basel) 2020;9:E802. [PMID: 33198311 DOI: 10.3390/antibiotics9110802] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Kaye KS, Rice LB, Dane AL, Stus V, Sagan O, Fedosiuk E, Das AF, Skarinsky D, Eckburg PB, Ellis-Grosse EJ. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis 2019;69:2045-56. [PMID: 30861061 DOI: 10.1093/cid/ciz181] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
97 Bjerklund Johansen TE, Kulchavenya E, Lentz GM, Livermore DM, Nickel JC, Zhanel G, Bonkat G. Fosfomycin Trometamol for the Prevention of Infectious Complications After Prostate Biopsy: A Consensus Statement by an International Multidisciplinary Group. Eur Urol Focus 2021:S2405-4569(21)00308-4. [PMID: 34920977 DOI: 10.1016/j.euf.2021.11.007] [Reference Citation Analysis]
98 Lee DS, Lee SJ, Choe HS. Community-Acquired Urinary Tract Infection by Escherichia coli in the Era of Antibiotic Resistance. Biomed Res Int 2018;2018:7656752. [PMID: 30356438 DOI: 10.1155/2018/7656752] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
99 Brown AR, Gordon RA, Hyland SN, Siegrist MS, Grimes CL. Chemical Biology Tools for Examining the Bacterial Cell Wall. Cell Chem Biol 2020;27:1052-62. [PMID: 32822617 DOI: 10.1016/j.chembiol.2020.07.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Moussa M, Abou Chakra M, Dellis A, Moussa Y, Papatsoris A. Pharmacotherapeutic advances for recurrent urinary tract infections in women. Expert Opin Pharmacother 2020;21:2011-26. [PMID: 32717156 DOI: 10.1080/14656566.2020.1795128] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Almeida F, Santos Silva A, Silva Pinto A, Sarmento A. Chronic prostatitis caused by extended-spectrum β-lactamase-producing Escherichia coli managed using oral fosfomycin-A case report. IDCases 2019;15:e00493. [PMID: 30766796 DOI: 10.1016/j.idcr.2019.e00493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
102 Wang S, Liu H, Mao J, Peng Y, Yan Y, Li Y, Zhang N, Jiang L, Liu Y, Li J, Huang X. Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin-Resistant Enterococcus faecium in a Hollow Fiber Infection Model. Front Microbiol 2021;12:779885. [PMID: 34970238 DOI: 10.3389/fmicb.2021.779885] [Reference Citation Analysis]
103 Lim TP, Teo JQ, Goh AW, Tan SX, Koh TH, Lee WH, Cai Y, Tan TT, Kwa AL. In Vitro Pharmacodynamics of Fosfomycin against Carbapenem-Resistant Enterobacter cloacae and Klebsiella aerogenes. Antimicrob Agents Chemother 2020;64:e00536-20. [PMID: 32571821 DOI: 10.1128/AAC.00536-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Baker TM, Satlin MJ. The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies. Leuk Lymphoma 2016;57:2245-58. [PMID: 27339405 DOI: 10.1080/10428194.2016.1193859] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
105 Jiang L, Xie N, Chen M, Liu Y, Wang S, Mao J, Li J, Huang X. Synergistic Combination of Linezolid and Fosfomycin Closing Each Other's Mutant Selection Window to Prevent Enterococcal Resistance. Front Microbiol 2020;11:605962. [PMID: 33633692 DOI: 10.3389/fmicb.2020.605962] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Darlow CA, da Costa RMA, Ellis S, Franceschi F, Sharland M, Piddock L, Das S, Hope W. Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Paediatr Drugs 2021;23:465-84. [PMID: 34435316 DOI: 10.1007/s40272-021-00465-z] [Reference Citation Analysis]
107 Baros Jorquera C, Moreno-Switt AI, Sallaberry-Pincheira N, Munita JM, Flores Navarro C, Tardone R, González-Rocha G, Singer RS, Bueno I. Antimicrobial resistance in wildlife and in the built environment in a wildlife rehabilitation center. One Health 2021;13:100298. [PMID: 34401457 DOI: 10.1016/j.onehlt.2021.100298] [Reference Citation Analysis]
108 He WY, Zhang XX, Gao GL, Gao MY, Zhong FG, Lv LC, Cai ZP, Si XF, Yang J, Liu JH. Clonal spread of Escherichia coli O101: H9-ST10 and O101: H9-ST167 strains carrying fosA3 and bla CTX-M-14 among diarrheal calves in a Chinese farm, with Australian Chroicocephalus as the possible origin of E. coli O101: H9-ST10. Zool Res 2021;42:461-8. [PMID: 34156173 DOI: 10.24272/j.issn.2095-8137.2021.153] [Reference Citation Analysis]
109 Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR, Hernández-Torres A, Merino de Lucas E, Escolà-Vergé L, Bereciartua E, García-Vázquez E, Pintado V, Boix-Palop L, Natera-Kindelán C, Sorlí L, Borrell N, Giner-Oncina L, Amador-Prous C, Shaw E, Jover-Saenz A, Molina J, Martínez-Alvarez RM, Dueñas CJ, Calvo-Montes J, Silva JT, Cárdenes MA, Lecuona M, Pomar V, Valiente de Santis L, Yagüe-Guirao G, Lobo-Acosta MA, Merino-Bohórquez V, Pascual A, Rodríguez-Baño J; REIPI-GEIRAS-FOREST group . Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial. JAMA Netw Open 2022;5:e2137277. [PMID: 35024838 DOI: 10.1001/jamanetworkopen.2021.37277] [Reference Citation Analysis]
110 Mueller L, Cimen C, Poirel L, Descombes MC, Nordmann P. Prevalence of fosfomycin resistance among ESBL-producing Escherichia coli isolates in the community, Switzerland. Eur J Clin Microbiol Infect Dis 2019;38:945-9. [PMID: 30877486 DOI: 10.1007/s10096-019-03531-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
111 Wenzler E, Meyer KM, Bleasdale SC, Sikka M, Mendes RE, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA. Ex Vivo Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects. Antimicrob Agents Chemother 2020;64:e02102-19. [PMID: 31767717 DOI: 10.1128/AAC.02102-19] [Reference Citation Analysis]
112 Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ, Shortridge D. Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves. Antimicrob Agents Chemother 2019;63:e02549-18. [PMID: 30858207 DOI: 10.1128/AAC.02549-18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
113 Liu Y, Li R, Xiao X, Wang Z. Molecules that Inhibit Bacterial Resistance Enzymes. Molecules 2018;24:E43. [PMID: 30583527 DOI: 10.3390/molecules24010043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
114 Tompkins K, van Duin D. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. Eur J Clin Microbiol Infect Dis 2021. [PMID: 34169446 DOI: 10.1007/s10096-021-04296-1] [Reference Citation Analysis]
115 Wenzler E, Ellis-Grosse EJ, Rodvold KA. Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers. Antimicrob Agents Chemother 2017;61:e00775-17. [PMID: 28630194 DOI: 10.1128/AAC.00775-17] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
116 Albiero J, Mazucheli J, Barros JPDR, Szczerepa MMDA, Nishiyama SAB, Carrara-Marroni FE, Sy S, Fidler M, Sy SKB, Tognim MCB. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase. Antimicrob Agents Chemother 2019;63:e00126-19. [PMID: 30910903 DOI: 10.1128/AAC.00126-19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]